Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

1. Atorvastatin

Atorvastatin Top results for atorvastatin - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for atorvastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. Importance: The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain. Objective: To determine if periprocedural loading doses of atorvastatin decrease 30-day major adverse cardiovascular events (MACE (...) to receive 2 loading doses of 80 mg of atorvastatin (n = 2087) or matching placebo (n = 2104) before and 24 hours after a planned PCI. All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication. Main Outcomes and Measures: The primary outcome was MACE, defined as a composite of all-cause mortality, myocardial infarction, stroke, and unplanned coronary revascularization through 30 days. Results: Among the 4191 patients (mean age, 61.8 [SD, 11.5

JAMA2018

3. Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial.

Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial. 27757177 2016 10 19 2017 02 24 8 8 2016 Aug Electronic physician Electron Physician Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial. 2700-2706 Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder with unknown etiology. Atorvastatin is a lipid-lowering agent that affects (...) the inflammatory processes. This study aimed to determine the anti-inflammatory effects of atorvastatin on the Disease Activity Index and high-density lipoprotein (HDL) concentrations in RA patients. This clinical trial was performed on 38 RA patients, who were referred to the Imam Reza and Ghaem Medical Centers of Mashhad, Iran between 2013 and 2014. Patients were divided into two groups: 1) the intervention group, which received 40 mg of atorvastatin, and 2) the control group. Response to treatment

Electronic physician2016 Full Text: Link to full Text with Trip Pro

4. Antagonistic Effect of Atorvastatin on High Fat Diet Induced Survival during Acute Chagas Disease

Antagonistic Effect of Atorvastatin on High Fat Diet Induced Survival during Acute Chagas Disease 27416748 2017 05 03 2018 11 13 1769-714X 18 11 2016 Nov Microbes and infection Microbes Infect. Antagonistic effect of atorvastatin on high fat diet induced survival during acute Chagas disease. 675-686 S1286-4579(16)30089-2 10.1016/j.micinf.2016.06.006 Chagasic cardiomyopathy, which is seen in Chagas disease, is the most severe and life-threatening manifestation of infection by the kinetoplastid (...) of diabetes and obesity in Latin America, the endemic regions for Chagas disease, has led to many patients in the endemic region of infection having hyperlipidemia that is being treated with statins such as atorvastatin. The current study was performed to examine mice fed on either regular or high fat diet for effects of atorvastatin on T. cruzi infection-induced myocarditis and to evaluate the effect of this treatment during infection on adipose tissue physiology and cardiac pathology. Atorvastatin

Microbes and infection2016 Full Text: Link to full Text with Trip Pro

5. LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs

LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs LIPTRUZET SUMMARY CT14103

Haute Autorite de sante2016

6. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.

High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. 26906014 2016 03 01 2016 03 08 2016 12 15 1538-3598 315 9 2016 Mar 01 JAMA JAMA High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. 877-88 10.1001/jama.2016.0548 Statins affect several mechanisms underlying acute kidney injury (AKI). To test the hypothesis that short-term high-dose perioperative atorvastatin would (...) reduce AKI following cardiac surgery. Double-blinded, placebo-controlled, randomized clinical trial of adult cardiac surgery patients conducted from November 2009 to October 2014 at Vanderbilt University Medical Center. Patients naive to statin treatment (n = 199) were randomly assigned 80 mg of atorvastatin the day before surgery, 40 mg of atorvastatin the morning of surgery, and 40 mg of atorvastatin daily following surgery (n = 102) or matching placebo (n = 97). Patients already taking a statin

JAMA2016

7. The Efficacy of Short-Term, High-Dose Atorvastatin in Prevention of Contrast-Induced Nephropathy in Patients with Impaired Renal Function

The Efficacy of Short-Term, High-Dose Atorvastatin in Prevention of Contrast-Induced Nephropathy in Patients with Impaired Renal Function "The Efficacy of Short-Term, High-Dose Atorvastatin in Prevention of Co" by Susanne E. Hotchkin < > > > > > Title Author Date of Award 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Jennifer VanAtta PA-C Rights . Abstract Background : Contrast-induced nephropathy (CIN) is a serious adverse (...) research has demonstrated controversial results of the use of short-term statin therapy for prevention of CIN. The aim of this systematic review is to evaluate the efficacy of atorvastatin in prevention of CIN in patients with renal impairment undergoing coronary angiography or percutaneous coronary intervention. Methods: An exhaustive search of available medical literature from MEDLINE-Ovid, MEDLINE-PubMed, and Google Scholar was performed using the search terms “contrast-induced nephropathy,” “acute

Pacific University EBM Capstone Project2016

8. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease 25595417 2015 02 14 2015 05 11 2015 11 19 1468-201X 101 5 2015 Mar Heart (British Cardiac Society) Heart High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. 356-62 10.1136/heartjnl-2014-306906 To study whether high-dose versus usual-dose statin treatment reduces the incidence of peripheral artery disease (PAD) and what is the effect (...) of high-dose statin treatment on cardiovascular disease (CVD) outcome in patients with PAD. In the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial, 8888 post-myocardial infarction patients were randomised to high-dose or usual-dose statin therapy (atorvastatin 80 mg/day vs simvastatin 20-40 mg/day). We investigated the effect of high-dose versus usual-dose statins on the pre-specified outcome PAD incidence, and additionally performed a posthoc analysis of the efficacy

EvidenceUpdates2015

9. Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia

Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia 24786356 2014 06 02 2014 07 18 2015 11 19 1879-1913 113 12 2014 Jun 15 The American journal of cardiology Am. J. Cardiol. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. 2021-9 10.1016 (...) /j.amjcard.2014.03.045 S0002-9149(14)00888-1 The cholesteryl ester transfer protein (CETP) inhibitor evacetrapib has been previously shown to increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) levels, as monotherapy or in combination with statins. In this study, 165 Japanese patients with elevated LDL-C or low HDL-C levels were randomly assigned to receive placebo, evacetrapib monotherapy 30 mg, 100 mg, or 500 mg, atorvastatin 10 mg

EvidenceUpdates2014

10. Efficacy of Topical Atorvastatin for the Treatment of Pressure Ulcers: A Randomized Clinical Trial

Efficacy of Topical Atorvastatin for the Treatment of Pressure Ulcers: A Randomized Clinical Trial 23940000 2014 01 08 2014 08 26 2015 11 19 1875-9114 34 1 2014 Jan Pharmacotherapy Pharmacotherapy Efficacy of topical atorvastatin for the treatment of pressure ulcers: a randomized clinical trial. 19-27 10.1002/phar.1339 To evaluate the effects of topical atorvastatin on the healing process of pressure ulcers in critically ill patients. Randomized, double-blind, placebo-controlled clinical trial (...) . Medical-surgical intensive care unit of a university-affiliated teaching hospital in Tehran, Iran. One hundred four patients with stage I or II pressure ulcers, graded according to the 2-digit Stirling Pressure Sore Severity Scale. Patients were randomized to receive topical atorvastatin 1% ointment (51 patients [atorvastatin group]) or placebo ointment (53 patients [control group]) applied once/day to pressure ulcers for 14 days in addition to standard care for pressure ulcers. The efficacy of each

EvidenceUpdates2013

11. Liptruzet (ezetimibe and atorvastatin)

Liptruzet (ezetimibe and atorvastatin) Drug Approval Package: Liptruzet (ezetimibe and atorvastatin) NDA #200153 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Liptruzet (ezetimibe and atorvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg Company: Merck Sharp & Dohme Corp. Application No.: 200153 Approval Date: 05/03/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2013

12. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Gandhi SK, Jensen MM, Fox KM, Smolen L (...) concluded that rosuvastatin was cost-effective, over a lifetime, compared with generic simvastatin or atorvastatin. The lack of detailed reporting and the highlighted limitations to this study mean that the authors’ conclusions should be considered with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective This study evaluated the long-term cost-effectiveness of alternative statin therapies in Swedish patients with a high risk of cardiovascular events

NHS Economic Evaluation Database.2012

13. Atorvastatin (Lipitor®) chewable tablets

Atorvastatin (Lipitor®) chewable tablets Atorvastatin (Lipitor®) chewable tablets Atorvastatin (Lipitor®) chewable tablets All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Atorvastatin (Lipitor®) chewable tablets. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1112. 2012 Authors' conclusions Atorvastatin (Lipitor®) chewable tablets are recommended as an option for use within NHS Wales: as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia

Health Technology Assessment (HTA) Database.2012

14. Use of atorvastatin in systemic lupus erythematosus in children and adolescents

Use of atorvastatin in systemic lupus erythematosus in children and adolescents 22031171 2012 01 06 2012 02 21 2017 02 20 1529-0131 64 1 2012 Jan Arthritis and rheumatism Arthritis Rheum. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. 285-96 10.1002/art.30645 Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy and safety in children and adolescents with systemic lupus erythematosus (SLE) are unknown (...) . This study was undertaken to determine the 3-year efficacy and safety of atorvastatin in preventing subclinical atherosclerosis progression in pediatric-onset SLE. A total of 221 participants with pediatric SLE (ages 10-21 years) from 21 North American sites were enrolled in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus study, a randomized double-blind, placebo-controlled clinical trial, between August 2003 and November 2006 with 36-month followup. Participants were randomized

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

15. Atorvastatin (Lipitor) - as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides

Atorvastatin (Lipitor) - as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides Published 12 March 2012 Product Update: In Confidence atorvastatin 10 and 20mg chewable tablets (Lipitor ® ) (No:766/12) Pfizer Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS (...) Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission Atorvastatin chewable tablets (Lipitor®) is accepted for use in NHS Scotland Indication under review: as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed

Scottish Medicines Consortium2012

16. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. 23113833 2012 11 15 2012 11 27 2016 11 25 1533-4406 367 20 2012 Nov 15 The New England journal of medicine N. Engl. J. Med. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. 1891-900 10.1056/NEJMoa1201832 Serum proprotein convertase subtilisin/kexin 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors, increasing the degradation of LDL receptors and reducing the rate (...) at which LDL cholesterol is removed from the circulation. REGN727/SAR236553 (designated here as SAR236553), a fully human PCSK9 monoclonal antibody, increases the recycling of LDL receptors and reduces LDL cholesterol levels. We performed a phase 2, multicenter, double-blind, placebo-controlled trial involving 92 patients who had LDL cholesterol levels of 100 mg per deciliter (2.6 mmol per liter) or higher after treatment with 10 mg of atorvastatin for at least 7 weeks. Patients were randomly assigned

NEJM2012

17. Generic Atorvastatin and Health Care Costs.

Generic Atorvastatin and Health Care Costs. Generic atorvastatin and health care costs. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22149736 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jan 19;366(3):201-4. doi: 10.1056/NEJMp1113112. Epub 2011 Dec 7. Generic atorvastatin and health care costs. 1 , , , , . 1 Western University of Health Sciences, Pomona, CA, USA. Comment in [N Engl J Med. 2012] PMID: 22149736 PMCID: DOI: [Indexed for MEDLINE] Images from this publication. Figure U.S. Statin Market Share Pre- and Post

NEJM2011 Full Text: Link to full Text with Trip Pro

18. Atorvastatin for the treatment of plaque-type psoriasis

Atorvastatin for the treatment of plaque-type psoriasis 22026392 2011 10 26 2012 02 07 2015 11 19 1875-9114 31 11 2011 Nov Pharmacotherapy Pharmacotherapy Atorvastatin for the treatment of plaque-type psoriasis. 1045-50 10.1592/phco.31.11.1045 To explore the efficacy and safety of oral atorvastatin for the treatment of plaque-type psoriasis. Prospective, randomized, double-blind, placebo-controlled study. University-affiliated psoriasis outpatient clinic in Iran. Forty-two patients aged 16-60 (...) years with a diagnosis of acute or chronic plaque-type psoriasis with body surface area (BSA) involvement of greater than 10% were enrolled; 40 completed the study. Intervention. Oral atorvastatin 40 mg/day (20 patients) or placebo (20 patients) was administered for 12 weeks; patients' topical therapies with emollients, keratolytics, and/or class V corticosteroids were continued during the study period. The Psoriasis Area and Severity Index (PASI) and percentage BSA involvement were used to assess

EvidenceUpdates2011

19. Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 21529740 2011 06 17 2011 08 23 2016 11 25 1879-1913 108 1 2011 Jul 01 The American journal of cardiology Am. J. Cardiol. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN (...) [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. 1-7 10.1016/j.amjcard.2011.03.001 Contrast-induced nephropathy (CIN) impairs clinical outcome in patients undergoing angiographic procedures. The aim of this study was to investigate whether short-term high-dose atorvastatin load decreases the incidence of CIN after percutaneous coronary intervention (PCI). Statin-naive patients with acute coronary syndrome undergoing PCI (n = 241) randomly received

EvidenceUpdates2011

20. Predictors of new-onset diabetes in patients treated with atorvastatin results from 3 large randomized clinical trials

Predictors of new-onset diabetes in patients treated with atorvastatin results from 3 large randomized clinical trials 21453832 2011 04 01 2011 06 14 2015 11 19 1558-3597 57 14 2011 Apr 05 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. 1535-45 10.1016/j.jacc.2010.10.047 We sought to examine the incidence and clinical predictors of new-onset (...) type 2 diabetes mellitus (T2DM) within 3 large randomized trials with atorvastatin. Statin therapy might modestly increase the risk of new-onset T2DM. We used a standard definition of diabetes and excluded patients with prevalent diabetes at baseline. We identified baseline predictors of new-onset T2DM and compared the event rates in patients with and without new-onset T2DM. In the TNT (Treating to New Targets) trial, 351 of 3,798 patients randomized to 80 mg of atorvastatin and 308 of 3,797 randomized to 10

EvidenceUpdates2011